1. General Information
|
2. Conditions
|
3. Catalogue Items
|
4. Attestation Documents
|
5. Contract Document
|
6. Budget Setting
General Information
Back To Top
Summary
Summary
Contract Unique Identifier
DO1.SLCNTR.557618
Contract reference
CECANOT-2021-00692
Contract description:
Adquisición de Metronidazol 5mg/ml, Solución para Perfusión I,V. y Amboxol 15mg/2ml Amp., para Abastecimeinto de Farmacia, Quirófanos y Unidades de COVID-19. Ref.CECANOT-DAF-CM-2021-0302.
Type of Contract
Goods
Contract Start:
21/09/2021 14:00:00
((UTC-04:00) Georgetown, La Paz, Manaus, San Juan)
Contract End:
22/10/2021 00:00:00
((UTC-04:00) Georgetown, La Paz, Manaus, San Juan)
Legally Binding?
Yes
Only Award Notice
Contract State
Accepted
Contracting Company Identification
Contracting Company Identification
Supplier Company Identification
Supplier Company Identification
Object Info
Object Info
E-Procurement Profile:
DGCP-01-ComprasMenores
Request Reference
CECANOT-DAF-CM-2021-0302
Request Title
Adquisición de Medicamentos para Abastecimiento de Farmacia, Quirófanos y Unidades de COVID-19.
Description
Adquisición de Medicamentos para Abastecimiento de Farmacia, Quirófanos y Unidades de COVID-19.
Business Operation
Farmacia
Reply Reference
CECANOT-DAF-CM-2021-0302
Type of Contract
GoodsDominicana
Contract Value
136,690 Dominican Pesos
Conditions
Back To Top
Financial & Delivery Conditions
Financial & Delivery Conditions
Delivery options
Transporte incluido
Contract Start Date
21/09/2021 14:00:00
((UTC-04:00) Georgetown, La Paz, Manaus, San Juan)
Contract End Date
21/10/2021 00:00:00
((UTC-04:00) Georgetown, La Paz, Manaus, San Juan)
Main site or location of works, place of delivery or performance
Calle Federico Velasquez # 1 Maria Auxiliadora OZAMA O METROPOLITANA DO
Payment Conditions
Payment Conditions
Payment Method
Invoice Payment Deadline
60 days
Contract Comments
Contract Comments
Comment:
1. SEGUN COTIZACIÓN NO. 1200091816 D/F 10-08-2021. 2. COTIZÓ AMBROXOL 15 MG EN AMPOLLAS 10/1.
Catalogue Items
Back To Top
1
DO1.PCCNTR.1186913 ContractData Container
1.1
-
Total sin descuentos
Valor del descuento
Total ITBIS
Total Otros Impuestos
Subtotal
Total
136,690.00
0.00
0.00
0.00
39,365.00
136,690.00
Referencia
Código UNSPSC
Cuenta presupuestaria
Descripción
Cantidad
Unidad
Precio unitario estimado
Precio unitario
Importe moneda orig. s/ITBIS
% Desc.
Descuento moneda original
Monto Gravado (Obras)
% ITBIS
ITBIS Moneda Original
% Otros Impuestos
Otros impuestos moneda original
Precio total estimado
Valor del precio de respuesta
2
51101603 - Metronidazol
2.3.4.1.01
METRONIDAZOL 5MG/ML. SOLUCIÓN PARA PERFUSIÓN, I.V.
600
UD
49
196.15
117,690.00
0
0.00
0
0
0.00
0
0.00
29,400.00
117,690.00
4
51102313 - Clorhidrato de
(...)
51102313 - Clorhidrato de rimantadina
2.3.4.1.01
AMBROXOL 15MG/2ML AMP.
500
UD
19.93
38
19,000.00
0
0.00
0
0
0.00
0
0.00
9,965.00
19,000.00
Attestation Documents
Back To Top
Contract Documents
Back To Top
Contract Document Template
Contract Document Template
Description
File Name
Contract Technical Document Mappings
Orden de Compras_23/8/2021_4_38 p.m..Pdf
Download
CUOTA A COMPROMETER SUED Y FARGESA_CM_2021_0302.pdf
CUOTA A COMPROMETER SUED Y FARGESA_CM_2021_0302.pdf
Download
ACTA DE ADJUDICACIÓN_CM_2021_0302.pdf
ACTA DE ADJUDICACIÓN_CM_2021_0302.pdf
Download
Budget Setting
Back To Top
Budget Settings
Budget Settings
Expenditure Objective
Operation
Source of Funds
Own resources
Manual Integration?
SNIP?
Yes
No
SNIP Code
Budget Total Value
136,690.00
DOP
Budget Appropriation Value
DOP
Account
Value
Annual Availability
2.3.4.1.01
136,690.00
DOP
----
View
Payment Calendar
ID
Description
Value
Month
Year
1
Adquisición de Metronidazol 5mg/ml, Solución para Perfusión I,V. y Amboxol 15mg/2ml Amp., para Abastecimeinto de Farmacia, Quirófanos y Unidades de COVID-19. Ref.CECANOT-DAF-CM-2021-0302.
136,690.00
DOP
Octubre
2021
Certificate of Appropriation
Year
Certificate Code
Certificate Version
Certificate Value
Certificate State
Certificate Link
2021
EG1630419632044EPtkA
100104326
136,690.00
DOP
Vencido
CUOTA A COMPROMETER SUED Y FARGESA_CM_2021_0302.pdf